Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Citrullination | 3 | 2025 | 35 | 1.120 |
Why?
|
| Benzimidazoles | 3 | 2023 | 54 | 0.890 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2023 | 10 | 0.860 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 322 | 0.830 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 628 | 0.610 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2023 | 480 | 0.600 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 734 | 0.440 |
Why?
|
| Apoptosis | 2 | 2024 | 1032 | 0.270 |
Why?
|
| Protein-Arginine Deiminases | 2 | 2023 | 85 | 0.260 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2023 | 61 | 0.260 |
Why?
|
| Nucleotidyltransferases | 2 | 2023 | 58 | 0.260 |
Why?
|
| Transcription Factor RelA | 1 | 2025 | 50 | 0.230 |
Why?
|
| Acute Lung Injury | 1 | 2025 | 43 | 0.230 |
Why?
|
| Siderophores | 1 | 2024 | 11 | 0.230 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2024 | 82 | 0.230 |
Why?
|
| High-Throughput Screening Assays | 1 | 2024 | 74 | 0.220 |
Why?
|
| Anthelmintics | 1 | 2024 | 42 | 0.220 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2024 | 89 | 0.220 |
Why?
|
| Cyclic GMP | 1 | 2023 | 28 | 0.220 |
Why?
|
| Herpes Simplex | 1 | 2023 | 48 | 0.210 |
Why?
|
| Citrulline | 1 | 2023 | 44 | 0.210 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 78 | 0.210 |
Why?
|
| Structure-Activity Relationship | 2 | 2024 | 365 | 0.210 |
Why?
|
| NAD | 1 | 2023 | 50 | 0.210 |
Why?
|
| Axons | 1 | 2023 | 118 | 0.200 |
Why?
|
| Proteome | 1 | 2023 | 141 | 0.200 |
Why?
|
| Osteogenesis | 1 | 2023 | 140 | 0.200 |
Why?
|
| Smad Proteins | 1 | 2022 | 21 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 129 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 804 | 0.200 |
Why?
|
| Macrophages | 2 | 2025 | 1015 | 0.200 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 258 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2023 | 169 | 0.190 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 155 | 0.190 |
Why?
|
| Proteins | 2 | 2023 | 730 | 0.180 |
Why?
|
| Sepsis | 1 | 2024 | 274 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 357 | 0.170 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2020 | 4 | 0.170 |
Why?
|
| DNA Topoisomerases | 1 | 2020 | 4 | 0.170 |
Why?
|
| Staphylococcus epidermidis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 22 | 0.170 |
Why?
|
| Cell Proliferation | 1 | 2024 | 941 | 0.170 |
Why?
|
| A549 Cells | 1 | 2020 | 36 | 0.170 |
Why?
|
| Indoles | 1 | 2020 | 106 | 0.160 |
Why?
|
| Quinazolines | 1 | 2019 | 21 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 191 | 0.160 |
Why?
|
| Quantum Dots | 1 | 2019 | 30 | 0.160 |
Why?
|
| Amino Acids | 1 | 2020 | 140 | 0.150 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 169 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2020 | 191 | 0.150 |
Why?
|
| Humans | 10 | 2025 | 59393 | 0.150 |
Why?
|
| HeLa Cells | 1 | 2020 | 526 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 170 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2023 | 850 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 147 | 0.140 |
Why?
|
| Escherichia coli | 1 | 2020 | 695 | 0.120 |
Why?
|
| Pseudomonas Infections | 2 | 2025 | 51 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2025 | 100 | 0.110 |
Why?
|
| Drug Discovery | 2 | 2024 | 89 | 0.110 |
Why?
|
| Bone Morphogenetic Protein Receptors | 2 | 2023 | 14 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 584 | 0.100 |
Why?
|
| Animals | 6 | 2025 | 19643 | 0.100 |
Why?
|
| Mice | 4 | 2025 | 10288 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 3230 | 0.070 |
Why?
|
| Trichuris | 1 | 2024 | 8 | 0.060 |
Why?
|
| Nematode Infections | 1 | 2024 | 11 | 0.060 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2024 | 12 | 0.060 |
Why?
|
| Ancylostoma | 1 | 2024 | 24 | 0.060 |
Why?
|
| Nematoda | 1 | 2024 | 34 | 0.060 |
Why?
|
| Small Molecule Libraries | 1 | 2024 | 55 | 0.060 |
Why?
|
| Extracellular Traps | 1 | 2024 | 41 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 114 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2024 | 374 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 94 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 90 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2023 | 193 | 0.050 |
Why?
|
| Wound Healing | 1 | 2023 | 174 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2022 | 46 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 305 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2024 | 587 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2023 | 253 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 169 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2023 | 460 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2023 | 313 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 1368 | 0.040 |
Why?
|
| Esterases | 1 | 2019 | 13 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2019 | 19 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 805 | 0.040 |
Why?
|
| Lysosomes | 1 | 2019 | 160 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1303 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2022 | 697 | 0.040 |
Why?
|
| Cell Survival | 1 | 2019 | 559 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2023 | 623 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1983 | 0.030 |
Why?
|
| Male | 2 | 2025 | 27730 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2023 | 2898 | 0.030 |
Why?
|